| 1 |
35110200 | PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment. | 2022 Jan |
3 |
| 2 |
35418130 | Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. | 2022 Apr 13 |
6 |
| 3 |
35547095 | Current status and advances of immunotherapy in nasopharyngeal carcinoma. | 2022 |
1 |
| 4 |
35586061 | c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer. | 2022 |
2 |
| 5 |
35615894 | Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report. | 2022 May 26 |
1 |
| 6 |
32894642 | Inhibition of NF-κB is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells. | 2021 Jan |
1 |
| 7 |
33626233 | Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. | 2021 Mar |
1 |
| 8 |
33694102 | Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression. | 2021 Jun |
2 |
| 9 |
34359638 | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. | 2021 Jul 25 |
1 |
| 10 |
34377158 | IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. | 2021 |
1 |
| 11 |
32019287 | Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. | 2020 Apr |
2 |
| 12 |
32500171 | [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology]. | 2020 Jul |
1 |
| 13 |
32517311 | Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. | 2020 Jun 7 |
3 |
| 14 |
31289485 | Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. | 2019 Jul |
2 |
| 15 |
31470128 | Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. | 2019 Dec |
1 |
| 16 |
29675791 | Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. | 2018 Jul |
1 |
| 17 |
28112370 | The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. | 2017 Mar |
2 |
| 18 |
25368235 | Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. | 2014 Nov |
1 |